- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06271538
Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome
A Randomized Double-Blind Placebo-controlled Clinical Trial on the Efficacy of Skål Pro (Lactobacillus Plantarum 299 and Galacto-oligosaccharides) in Improving Severity of Symptoms, Stool Forms, Quality of Life and Psychological Dysfunction in Patients With Irritable Bowel Syndrome (IBS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Irritable bowel syndrome (IBS) is a condition linked to disturbances in the gut-brain axis and dysbiosis. Although probiotic modulation of dysbiosis appears promising for IBS treatment, identifying the specific beneficial strains remains uncertain. Furthermore, even with an effective probiotic strain, variations in efficacy among populations are observed due to environmental heterogeneity, particularly dietary influences.
This study seeks to provide efficacy insights into Skal Pro powder 2g (containing Lactobacillus plantarum 299v 1x10^10 colony forming unit (CFU) and GOS), shedding light on the unique mechanisms of LP299V within the Malaysian population through a randomized controlled trial (RCT).
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Jonathan Khor
- Phone Number: +60122888024
- Email: jonathankhor@epplusgroup.com
Study Locations
-
-
Kelantan
-
Kubang Kerian, Kelantan, Malaysia, 16150
- Hospital Universiti Sains Malaysia
-
Principal Investigator:
- Yeong Yeh Lee, MD, PhD
-
Contact:
- Yeong Yeh Lee, MD, PhD
- Phone Number: 6845 +6097676846
- Email: yylee@usm.my
-
Sub-Investigator:
- Thai Hau Koo, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- IBS diagnosed using the Rome IV criteria
- Age above 18 years old and any gender
- Any subtypes of IBS (diarrhea, constipation or mixed)
Exclusion Criteria:
- Presence of red flag symptoms (weight loss, anemia, night symptoms, abdominal mass, strong family history of cancer)
- Was prescribed antibiotic (s) within the past one month
- Medical conditions that contraindicate probiotic use including severe sepsis and pregnancy
- Presence of bowel malignancy
- Diagnosis of bowel infection within the past one month
- Previous abdominal surgeries
- Patients with overt psychiatric illnesses including schizophrenia and manic disorders
- A history of allergy to probiotic
- Was prescribed probiotic (s) within the past one month
- Was previously prescribed probiotic Skal Pro™ (LP299V™)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Skal Pro
Skal Pro in the form of 2g sachet powder contains 10 billion CFU of freeze-dried Lactobacillus plantarum 299v (LP299V) and galactooligosaccharides (GOS).
|
One sachet Skal Pro per day containing Lactobacillus plantarum 299v 1x10^10 CFU and GOS
|
Placebo Comparator: Placebo
Placebo is an oral formulation of inert powder.
Placebo and Skal Pro are identical in shape, size, colour, packaging and taste.
|
One sachet per day identical in shape, size, colour, packaging and taste to the Skal Pro sachet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improving the severity of symptoms in individuals with IBS, assessed by IBS Symptom Severity Scale (IBSSSS)
Time Frame: Assessed at baseline, Week 1, Week 2, and Week 4.
|
IBSSS questionnaire contains five questions that measures, on a 100-point visual analogue scale (VAS), the severity of abdominal pain, the frequency of abdominal pain, the severity of abdominal distension, dissatisfaction with bowel habits, and interference with quality of life (QOL).
All five components contribute to the scores equally, yielding a theoretically range of 0 - 500, with a higher score indicating worse condition.
The Malay version questionnaire will be used.
|
Assessed at baseline, Week 1, Week 2, and Week 4.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in stool frequency and satisfaction after passing stool, assessed by daily stool diary
Time Frame: Assessed daily from baseline to Week 4.
|
Daily diary of number of bowel movements.
|
Assessed daily from baseline to Week 4.
|
Change in Visceral Sensitivity Index
Time Frame: Assessed at baseline, Week 1, Week 2, and Week 4.
|
The Visceral Sensitivity Index (VSI) is a 15-item questionnaire which measures gastrointestinal symptom-specific anxiety.
Replies to each item are provided on a 6-point scale from "strongly disagree" (scored as 0) to "strongly agree" (scored as 5).
A Malay version of the questionnaire was developed using standard forward-back translation procedures.
The Malay version questionnaire will be used.
|
Assessed at baseline, Week 1, Week 2, and Week 4.
|
Assessment of psychological dysfunction suing Catastrophizing Questionnaire
Time Frame: Assessed at baseline, Week 1, Week 2, and Week 4.
|
The Coping Strategies Questionnaire (CSQ) - Catastrophizing (CAT) subscale consists of six questions on a 6-point Likert scale, with response options ranging from 0 (never) to 5 (very frequently).
The Malay version questionnaire will be used.
|
Assessed at baseline, Week 1, Week 2, and Week 4.
|
Change in stool consistency (Bristol Stool Scale), assessed by daily stool diary
Time Frame: Assessed daily from baseline to Week 4.
|
Daily diary of stool consistency of each bowel movement based on Bristol Stool Scale (Type 1-7), from type 1-2 = separate hard lump stool, type 3-4= ideal stool, type 5-7 =loose stool
|
Assessed daily from baseline to Week 4.
|
Change in abdominal bloating, assessed by Bloating Severity Questionnaire (BSQ)
Time Frame: Assessed at baseline, Week 1, Week 2, and Week 4.
|
Originally developed by Thiwan et al., this research group then translated and validated the BSQ in the Malay language (BSQ-M) [13].
There are 2 sub-scales, the 6-item Sev-Gen (Severity-General) and 5-item Sev-24 (Severity-24 hour) with responses in seven-point Likert scale on different degree of severity (from 1 = never to 7=always).
For this study, only the Sev-Gen will be used.
|
Assessed at baseline, Week 1, Week 2, and Week 4.
|
Improvement in Quality of Life, assessed by EQ-5D-5L Questionnaire
Time Frame: Assessed at baseline, Week 1, Week 2, and Week 4.
|
The 5-level EQ-5D version (EQ-5D-5L) was introduced by the EuroQol Group in 2009, and consist of 2 sections, 1) the EQ-5D descriptive system and 2) the EQ visual analogue scale (EQ VAS).
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain or discomfort and anxiety/depression.
Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems.
The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health the participant can imagine' and 'The worst health the participant can imagine'.
The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.
The Malay version questionnaire will be used.
|
Assessed at baseline, Week 1, Week 2, and Week 4.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yeong Yeh Lee, MD, PhD, Hospital Universiti Sains Malaysia
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EP-USM-122023-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Diseases
-
Umeå UniversityRecruitingFunctional Gastrointestinal DisorderSweden
-
The University of Texas Medical Branch, GalvestonCompletedGastrointestinal Disorders, Functional
-
Campus Bio-Medico UniversityRecruitingGastrointestinal Cancer | Gastrointestinal Hemorrhage | Gastrointestinal Lesions | Gastrointestinal Injury | Gastrointestinal Perforation | Gastrointestinal UlcerItaly
-
Chang Gung Memorial HospitalNew Bellus EnterprisesUnknownNeoplasm | Functional Gastrointestinal DisorderTaiwan
-
Massachusetts General HospitalEnrolling by invitationGastrointestinal Dysfunction | Gastrointestinal DiseaseUnited States
-
Dr Anne PayneUniversity of LondonUnknownFunctional Gastrointestinal Disorders in ChildrenUnited Kingdom
-
Jiangxi University of Traditional Chinese MedicineThe First Affiliated Hospital of Nanchang University; Second Affiliated Hospital... and other collaboratorsCompletedGastrointestinal DiseaseChina
-
Indiana UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingFunctional Gastrointestinal DisordersUnited States
-
Beth Israel Deaconess Medical CenterCompleted
-
Nationwide Children's HospitalCompletedFunctional Gastrointestinal DisordersUnited States
Clinical Trials on Skal Pro
-
The University of Texas Medical Branch, GalvestonCompletedDiet | Protein | Skeletal MuscleUnited States
-
Cairo UniversityUnknown
-
Abramson Cancer Center at Penn MedicineNational Cancer Institute (NCI)Recruiting
-
United States Army Research Institute of Environmental...Eastern Michigan UniversityCompletedWeight Loss | Other Effects of High AltitudeUnited States
-
North Florida Foundation for Research and EducationPfizer; US Department of Veterans AffairsUnknownRheumatoid ArthritisUnited States
-
Bolton MedicalActive, not recruitingAortic Dissection Type BUnited States
-
National Cancer Institute (NCI)RecruitingProstate CancerUnited States
-
Rigshospitalet, DenmarkNovo Nordisk A/SCompletedHematologic MalignancyDenmark
-
Universitätsklinikum Hamburg-EppendorfCompletedFluid Overload | Bloodpressure | Volume Overload | Hemodynamic Rebound
-
Mindmaze SAEcole Polytechnique Fédérale de Lausanne; Clinique Romande de ReadaptationCompletedMotor Disorders | Chronic StrokeSwitzerland